Of these, RIC has the most robust clinical evidence, especially in the context of STEMI, but also emerging for other indications such as acute ischemic stroke and aneurysmal subarachnoid hemorrhage. Neonatal thrombosis
Treatment options for full-term and preterm babies who develop thromboembolism include expectant management (with careful observation), nitroglycerin ointment, pharmacological therapy (thrombolytics and/or anticoagulants), and surgery. The evidence supporting these treatment approaches is weak. For anticoagulant treatment, t is not clear if unfractionated and/or low molecular weight heparin treatment is effective at decreasing mortality and serious adverse events in this population. There is also insufficient evidence to understand the risk of adverse effects associated with these treatment approaches in term or preterm infants. See also
Blood clotting tests
Disseminated intravascular coagulation
Hepatic artery thrombosis
Thrombotic microangiopathy

References
Bibliography
Brunner, Lillian (2010). Brunner & Suddarths textbook of medical-surgical nursing. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins. ISBN 978-0781785907. Copstead, Lee (2013). Pathophysiology. St. Louis, Mo: Elsevier. ISBN 978-1455726509. Hoffman, Barbara (2012). Williams gynecology. New York: McGraw-Hill Medical. ISBN 978-0071716727. Moliterno, David (2013). Therapeutic advances in thrombosis. Chichester, West Sussex: Wiley-Blackwell. ISBN 978-1405196253. Abele, H (2014). Atlas of gynecologic surgery. Stuttgart: Thieme. ISBN 978-3136507049; Access provided by the University of Pittsburgh{{cite book}}:  CS1 maint: postscript (link)

External links
 Media related to Thrombosis at Wikimedia Commons
Thrombosis at Curlie
Cause
Cherry angiomas appear spontaneously in many people in middle age but can also, less commonly, occur in young people. They can also occur in an aggressive eruptive manner in any age. The underlying cause for the development of cherry angiomas is not understood. Cherry angioma may occur through two different mechanisms: angiogenesis (the formation of new blood vessels from pre-existing vessels), and vasculogenesis (the formation of totally new vessels, which usually occurs during embryonic and fetal development).One study published in 2010 found that a regulatory nucleic acid suppresses protein growth factors that cause vascular growth. This regulatory nucleic acid was lower in tissue samples of hemangiomas, and the growth factors were elevated, which suggests that the elevated growth factors may cause hemangiomas. The study found that the level of microRNA 424 is significantly reduced in senile hemangiomas compared to normal skin resulting in increased protein expression of MEK1 and cyclin E1. By inhibiting mir-424 in normal endothelial cells they could observe the same increased protein expression of MEK1 and cyclin E1 which, important for the development of senile hemangioma, induced cell proliferation of the endothelial cells. They also found that targeting MEK1 and cyclin E1 with small interfering RNA decreased the number of endothelial cells. A study published in 2019 identified that somatic mutations in GNAQ and GNA11 genes are present in many cherry angiomas. These specific missense mutations found in hemangiomas are also associated with port-wine stains and uveal melanoma.